<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01412489</url>
  </required_header>
  <id_info>
    <org_study_id>K 100801</org_study_id>
    <nct_id>NCT01412489</nct_id>
  </id_info>
  <brief_title>Intrauterine Adhesion Rate After Hysteroscopic Myomectomy and Application of HYALOBARRIER Gel</brief_title>
  <acronym>HYGEM</acronym>
  <official_title>Prevention of Postsurgical Uterine Synechia With HyalobarrierR Gel Endo in Hysteroscopic Myomectomy : a Prospective Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the intrauterine adhesion rate after the application&#xD;
      of HYALOBARRIER Gel at the end of hysteroscopic myomectomy. Secondary endpoints were&#xD;
      tolerance and side effect and subsequent fertility.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hysteroscopic myomectomy is the referent surgical treatment for submucous myoma. But&#xD;
      intrauterine adhesion rate was evaluated about 7 to 15% after this procedure. The&#xD;
      investigators hypothetically believe that application of HYALOBARRIER Gel at the end of the&#xD;
      procedure, could be reduce the mean intrauterine rate to 50%. Thus, the investigators&#xD;
      performed a multicenter (n = 20) prospective study non randomized in 220 patients with&#xD;
      submucous myoma &lt; 3 cm of diameter, evaluated by preoperative ultrasound. The investigators&#xD;
      prefer this study design, because the principal reason is the number of enrolled patient were&#xD;
      more 200 patients in each group with a double blind randomized study. Now, in all patients,&#xD;
      after hysteroscopic myomectomy which performed with a same technique in each center (bipolar&#xD;
      coagulation and physiologic serum), a diagnostic hysteroscopy was performed at 2 month to&#xD;
      determinate the existence of intrauterine adhesion. Secondary end points were in this study&#xD;
      the tolerance and side effects of HYALOBARRIER Gel and the subsequent fertility at 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The formation of postsurgical uterine synechiae rate with HyalobarrierR Gel Endo in hysteroscopic myomectomy</measure>
    <time_frame>between 4 and 8 weeks after initial hysteroscopic myomectomy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the number of participants with adverse events as a measure of safety and tolerability during the time of the study</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postsurgical fertility with evaluation of number of participants who became pregnant after surgery, spontaneously and/or after assisted reproductive technologies</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">189</enrollment>
  <condition>Myoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HYALOBARRIER Gel</intervention_name>
    <description>For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 45 aged-patients&#xD;
&#xD;
          -  hysteroscopic diagnosis of one submucous myoma with less than 3cm diameter requiring&#xD;
             operative hysteroscopy with saline type 0, 1 or 2&#xD;
&#xD;
          -  negative plasmatic βHCG test&#xD;
&#xD;
          -  non opposition&#xD;
&#xD;
          -  patients with social security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  multiple submucous myomas type 0, 1 or 2&#xD;
&#xD;
          -  presurgical embolization&#xD;
&#xD;
          -  presurgical impregnation with GnRH agonist&#xD;
&#xD;
          -  coagulative disorders&#xD;
&#xD;
          -  malignancies&#xD;
&#xD;
          -  uncontrolled diabetes&#xD;
&#xD;
          -  operative hysteroscopy with glycine&#xD;
&#xD;
          -  known hypersensitivity to HyalobarrierR Gel Endo&#xD;
&#xD;
          -  infection of the surgical area concerned&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis Benifla, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Gynecologie-Obstetrique, Hopital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>May 16, 2011</study_first_submitted>
  <study_first_submitted_qc>August 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2011</study_first_posted>
  <last_update_submitted>March 24, 2017</last_update_submitted>
  <last_update_submitted_qc>March 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine synechiae</keyword>
  <keyword>HyalobarrierR Gel Endo</keyword>
  <keyword>Operative hysteroscopy</keyword>
  <keyword>submucous myoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

